|
| Home : Scott Pink, Special Counsel, O'Melveny & Myers LLP to Speak at TKG’s The HIPAA Privacy Rule and COVID-19: Trends, Developments, Compliance Issues |
|
May 22
2020 |
Scott Pink, Special Counsel, O'Melveny & Myers LLP to Speak at TKG’s The HIPAA Privacy Rule and COVID-19: Trends, Developments, Compliance Issues |
|
The Knowledge Group, the leading producer of regulatory focused webcasts, has announced today that Scott Pink, Special Counsel, O'Melveny & Myers LLP will speak at its webcast entitled, “The HIPAA Privacy Rule and COVID-19: Trends, Developments, and Compliance Issues in the Current Pandemic.” |
|
This event is scheduled for Thursday, May 28, 2020 from 12:00 pm to 1:30 pm (ET).
For further details, please visit:
https://www.theknowledgegroup.org/webcasts/hipaa-privacy-rule/
About Scott Pink
A former general counsel for a major media company, Scott Pink brings an insider’s perspective to his broad-based practice. It’s what’s made him the lead outside advertising and marketing counsel to several well-known brands, and a sought-after resource on intellectual property, privacy and cybersecurity issues. He advises technology, media, entertainment and a variety of consumer product and franchise companies on issues of intellectual property counseling; social media law; cybersecurity and privacy; and advertising, marketing, and promotions law. Scott had led many privacy and security compliance initiatives worldwide for clients, including GDPR compliance, HIPAA compliance audits, compliance with financial security regulations (NYDFS) and security audits for cryptocurrency and blockchain companies. He is a thought leader on GDPR issues, having published articles in Cybersecurity Law Report and speaking at conferences hosted by the International Association of Privacy Professional.
About O'Melveny & Myers LLP
O’Melveny is a global law firm with approximately 750 lawyers in 15 offices worldwide committed to helping clients grow, protect their assets, and navigate the challenges of complex law and regulation. Across issues and industries, O’Melveny’s team brings depth and creativity to every challenge. For a full list of the firm’s capabilities, visit www.omm.com/services
Abstract
The current COVID-19 pandemic has created unprecedented challenges for health care providers and their business associates. This public health emergency has changed the way health care providers operate and deliver health care, including the increasing reliance on telehealth. Privacy officers for covered entities and their business associates need to keep abreast of notices and guidances issued by Department of Health and Human Services regarding compliance with Health Insurance Portability and Accountability Act (HIPAA) during this public health emergency.
With the constantly evolving regulatory developments and changes in health care delivery emerging in this area, potential risks and challenges are expected to rise alongside other existing issues, making compliance even more important.
In this LIVE Webcast, privacy law experts Scott Pink (O'Melveny & Myers LLP) and Christine Moundas (Ropes & Gray LLP) will provide the audience with an in-depth analysis of the recent trends in the HIPAA Privacy Rule in light of the COVID-19 pandemic. Speakers will present significant recent regulatory developments and compliance issues posed by this crisis. They will also provide best practices to stay compliant.
About The Knowledge Group
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/. |
| Source:https://www.1888pressrelease.com/scott-pink-special-counsel-o-melveny-myers-llp-to-speak-pr-674902.html |
| |
|
Related News
|
» The Knowledge Group Has Scheduled a Live Webcast on The HIPAA Privacy Rule and COVID-19: Trends, Developments, and Compliance Issues
» Hikma receives FDA approval for its generic Vascepa®
|
|
|
